Who
Mette Kirstine Agger
Director
Company insider
Files Form 4 as: Director, Lexeo Therapeutics; Director and 10% owner, scPharmaceuticals; Director and 10% owner, Enliven Therapeutics; Director, Trevi Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 3
- Sells
- 0
- Bought
- $15.9M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 21 Nov 2017
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —19,750 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —19,750 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,300 at $0.00 | filing |
| 9 Jun 2020filed 11 Jun 2020 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,124 at $0.00 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —478,749 at $0.00 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,470,492 at $0.00 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,894,444 at $0.00 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,457 at $0.00 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,245,222 | filing |
| 16 Mar 2020filed 16 Mar 2020 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.0M187,500 at $16.00 | filing |
| 18 Jun 2019filed 20 Jun 2019 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,124 at $0.00 | filing |
| 9 May 2019filed 13 May 2019 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —6,849,315 at $0.00 | filing |
| 9 May 2019filed 13 May 2019 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code C | —776,544 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Mette Kirstine Agger; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.